Yazar "Aybak, M" seçeneğine göre listele

Listeleniyor 1 - 4 / 4
  • [ X ]
    Öğe
    All-trans retinoic acid
    (Medimond S R L, 2000) Ayyildiz, O; Aybak, M; Tiftik, N; Müftüoglu, E
    The introduction of all-trans retinoic acid (ATRA) has further changed the manage-ment of acute promyelocytic leukemia (APL). After using of ATRA, the rate of early death and relapse has decreased dramatically. From February 1997 to March 2000, 12 consecutive patients with APL were treated with ATRA at an oral dose of 45mg/m(2)/d alone or in combination with chemotherapy. In 11 cases treated with ATRA alone, 11 (100%) achieved complete remission (CR) between 35-68 days. The other patient treated with ATRA+Daunorubicin died from central nervous system hemorrhage on the fourth day of treatment. The side effects were relatively mild as compared with chemotherapy. Retinoic acid syndrome was seen in two patients and successfully treated with dexamethasone. Among 11 patients closely followed after CR, 1 died at first relapse. In conclusion; ATRA has been able to induce a very high CR rate in newly diagnosed APL and has less toxic and tolerable side effects.
  • [ X ]
    Öğe
    Effect of oral pyridoxine hydrochloride supplementation on arterial blood pressure in patients with essential hypertension
    (Ecv-Editio Cantor Verlag Medizin Naturwissenschaften, 1995) Aybak, M; Sermet, A; Ayyildiz, MO; Karakilcik, AZ
    The purpose of this study was to test the effect of vitamin B-6 (pyridoxine-HCl, CAS 58-56-0) supplementation on arterial blood pressure in essential hypertension. The trial comprised 9 normotensive subjects (7 men and 2 women, aged between 32-58 years, mean +/- SD, 48 +/- 11) and 20 patients with essential hypertension (16 men and 4 women, aged between 32-69 years, mean +/- SD, 56 +/- 12). The patients were treated during 4 weeks with a single oral dose of pyridoxine (5 mg/kg body weight/day). After a 5-min rest, measurements were made in the supine position. When compared with the normotensive subjects, the hypertensive subject group had a significantly higher systolic and diastolic blood pressure (p < 0.001) and higher level of plasma norepinephrine (E) (p < 0.01) before pyridoxine treatment. On the other hand there, were no significant differences in plasma epinephrine (E) and heart rates. Treatment of hypertensive patients with pyridoxine significantly reduced systolic (p < 0.01) and diastolic blood pressure (p < 0.005), plasma NE (p < 0.005) and E (p < 0.05) within 4 weeks. However, there was no significant difference in heart rate at the end of pyridoxine treatment. These results indicate a relationship between pyridoxine status and arterial blood pressure in the essential hypertensive patients.
  • [ X ]
    Öğe
    Effect of Ramadan fasting on platelet aggregation in healthy male subjects
    (Springer, 1996) Aybak, M; Turkoglu, A; Sermet, A; Denli, O
    The purpose of this study was to examine platelet aggregation during Ramadan fasting. A group of 20 healthy non-smoking male volunteers were studied, whose mean age was [21 (SD 2.4) years range 19-24]. The average fast was about 15 h. Venous blood samples were taken on 4 different days; 1 day before Ramadan (day 0), then on the 1st, 14th and 28th day of Ramadan, On each of these 4 days, blood samples were taken at 4 p.m. (1 h before the evening meal). Body mass index and platelet count did nor change during fasting. Bleeding and coagulation time had increased significantly by the end of Ramadan fasting (P < 0.05, P < 0.005 respectively), but these changes remained within physiological Limits. Ramadan fasting induced a reduction in platelet sensitivity to adenosine 5'-diphosphate (ADP) and collagen on days 14 (P < 0.05) and 28 (P < 0.05, P < 0.005 respectively). However, adrenaline-induced. platelet aggregation decreased only on day 25 (P < 0.05). This study indicated that Ramadan fasting led to a decrease in the platelet responses of different aggregating agents (ADP, adrenaline and collagen) in vitro. It also led to an increase in bleeding and coagulation time.
  • [ X ]
    Öğe
    Prothrombin G20210A gene mutation with LightCycler polymerase chain reaction in venous thrombosis and healthy population in the southeast of Turkey
    (Springer, 2004) Ayyildiz, O; Kalkanli, S; Batun, S; Aybak, M; Isikdogan, A; Tiftik, N; Bolaman, Z
    Venous thrombosis (VT) is a common disease, with an annual incidence in the general population of approximately 1 per 1000. The prevalence of genetic risk factors for thrombosis varies greatly in different parts of the world. Prothrombin G20210A (PT G20210A) gene mutation has been recently identified as a common risk factor in venous thrombosis. Sixty-one patients with VT, differing in age and sex, and 340 healthy subjects were consecutively enrolled into our study to determine the prevalence of PT G20210A in VT and in the healthy population of the southeast of Turkey. The mutation was identified with fluorescence resonance energy transfer (FRET) with the LightCycler polymerase chain reaction. The PT G20210A mutation was found to be 6.5% (4/61) in the VT group and 1.2% (4/340) in the healthy group (P = 0.021). Three patients with VT had a heterozygous PT G20210A mutation, and the other patient with VT had both Factor V Leiden and PT G20210A mutations. We showed that this method may be used safely for detection of the PT G20210A gene mutation, and the prevalence of PT G20210A mutation is significantly higher in patients with VT than in the healthy population in the southeast of Turkey.